SITC Launches Immunotherapy-Focused Clinical Practice Guidelines Mobile Application | New


MILWAUKEE, September 16, 2021 / PRNewswire-PRWeb / – The Cancer Immunotherapy Society (SITC) has launched a new mobile app. The SITC Clinical Practice Guidelines (CPG) mobile app is the first and only free open access resource providing easy access to portable devices to recommendations on important aspects of immunotherapy treatment to help clinicians provide patients with cancer the hope of a longer survival, a better quality of life, and even, in some cases, a cure.

Immunotherapy is the standard of care for many cancers and SITC is the world’s leading member-driven organization dedicated specifically to improving cancer patient outcomes by advancing the science and application of immunotherapy. cancer. As such, a key strategic initiative for the company is to set standards for the field, including CPGs that help clinicians determine how and when to treat their patients with immunotherapy.

“SITC’s CPGs have become the gold standard for immunotherapy recommendations from the world’s leading experts,” says Ashish M. Kamat, MD, MBBS, FACS, Chair, SITC Cancer Immunotherapy Guidelines Oversight Committee. “As the field and available technology have advanced, the CPG application is a natural evolution to provide clinicians with advice on key considerations for immunotherapy, such as biomarkers, treatment selection, response monitoring, patient support and quality of life. “

Designed for busy physicians, nurses and other advanced practice providers, the SITC CPG mobile app is a one-stop-shop for SITC CPGs, educational webinars, books, clinician and patient resources, and more. Again.

“Our field is changing rapidly and busy clinicians need a quick reference guide for our recommendations and updates to our guidelines when new practice changing data becomes available,” said the President of SITC. Patrick hwu, MD. “The SITC CPG mobile app will be a valuable resource for cancer care providers, providing guideline information and interactive tools to help design and implement an immunotherapy treatment plan in a condensed and easily accessible format, wherever clinicians have access to a smartphone. “

Main features of the application

  • Timely updates to published CPGs when new data or approvals changing practice become available
  • Clear and simple navigation to quickly find relevant recommendations
  • Tools and interactive boards at your fingertips to support clinical decision-making
  • Toxicity-specific CPGs and ARI management support tools
  • Capabilities to create bookmarks and annotations for future reference
  • Advanced search functions for quick access to information on disease parameters, agents or specific toxicities
  • Supportive educational offers to improve understanding of guideline recommendations

“SITC is committed to making cancer immunotherapy a standard of care and the word ‘cure’ a reality for cancer patients around the world, which is why we are making this app free to all. oncology community, ”Hwu said.

For more information and to explore or download the SITC CPG mobile app, please visit

About the SITC Cancer Immunotherapy Guidelines

The new SITC Clinical Practice Guidelines mobile app is part of the larger SITC Cancer Immunotherapy Guidelines Program which has produced a collection of a collection of clinical practice guidelines (CPGs) developed by multidisciplinary expert groups who also draw on their own practical experience. as evidence in published literature and clinical trial data to develop evidence-based and consensus-based recommendations on when and how to use immunotherapy to help improve outcomes for cancer patients. You can read the entire CPG series in the Journal for ImmunoTherapy of Cancer (JITC), the company’s open-access, peer-reviewed online journal.

SITC’s expanding catalog of CPG covers disease-specific guidelines for several solid tumors including, but not limited to, head and neck cancer, lung cancer, and cancers Genitourinary, among other parameters, guidelines on hematologic malignancies, as well as tumor agnostic toxicity guidelines to help clinicians manage immune system-related adverse events. GICs are continuously evaluated for potential updates as new data becomes available.

About the Cancer Immunotherapy Society

Founded in 1984, the Society for Immunotherapy of Cancer (SITC) is a non-profit organization of healthcare professionals dedicated to improving the outcomes of cancer patients by advancing development, science and application of cancer immunotherapy and tumor immunology. SITC is made up of influential fundamental and translational scientists, practitioners, healthcare professionals, government leaders, and industry professionals from around the world. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to someday make the word “cure” a reality for cancer patients around the world. Learn more about SITC, our educational offerings and other resources at and follow us on Twitter, LinkedIn, Facebook and YouTube.



NOTE TO MEDIA: SITC may provide application demo, graphics, info, details, etc.

Media contact

Thomas martin, The Cancer Immunotherapy Society, 414-313-6679, [email protected]

Twitter, LinkedIn

SOURCE The Cancer Immunotherapy Society

Source link


Leave A Reply